Hytn Innovations Inc · CSE:HYTN
Hytn Innovations — Investor Presentation (2025)
17 slides from Hytn Innovations's investor presentation, 2025
Slide 1: HYTN Innovations Corporate Presentation 2025
HYTN INNOVATIONS GMP PROCESSING CANNABIS PRODUCT MANUFACTURING PSYCHEDELIC DRUG DEVELOPMENT PSYCOACTIVE AND PSCYCOTROPIC COMPOUND DEVELOPMENT CORPORATE PRESENTATION 2025 CSE: HYTN
Slide 2: Who We Are
Who We Are HYTN Innovations (HYTN) is a GMP certified Canadian company specializing in the development of psychoactive and psychotropic products. HYTN supplies products for highly regulated applications including products for global medicinal, clinical and recreational markets.
Slide 3: What We Do
What We Do We are revolutionizing the delivery of natural medicines to patients worldwide. HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. Our mission is to become the leading provider of
Slide 4: Company Highlights
Company Highlights By maximizing its capacity and capabilities HYTN is well positioned to realize revenues from legal medical and recreational markets while also developing long term clinical assets, Active Pharmaceutical Ingredients (API’s) and New Chemical Entities (NCE’s) Strategically Positioned
Slide 5: Licenses and Certifications
Licenses and Certifications HYTN possesses a full suite of licenses, guaranteeing products are compliant and manufactured to the highest global standards GMP Drug Establishment Certificate Complies with the Good Manufacturing cGMP Drug EUR-Lex & EudraGMDP Therapeutic Goods Administration, Practice r
Slide 6: Regulatory First Approach
Regulatory First Approach HYTN is committed to a regulatory first approach to product development. The company is compliant with all Canadian laws, and laws of all countries in which it does business. HYTN does not participate in any product development activities with organizations that are regulat
Slide 7: Facility Overview
Facility Overview A custom-built facility designed for innovative & scalable manufacturing The facility is capable of processing and producing a wide range of products, including: GMP Processing Active Pharmaceutical New Chemical Beverages Edibles Emulsions Topicals Tissue Cultures Tinctures And pac
Slide 8: Diversification Across Multiple Market Segments
Diversification Across Multiple Market Segments GMP Medical Pharmaceutical Recreational HYTN’s GMP certification makes it one of HYTN has successfully developed and HYTN is fully licensed under the Cannabis Act the only processors with the ability to commercialized products for physician use. and is
Slide 9: One of the Rare Few
One of the Rare Few 926 Active Canadian Cannabis Licenses 17 With GMP Processing Capability 7 With CDSL Capability 5 With Drug Establishment License HYTN is processing cannabis flower into HYTN is the only company to be selling GMP finished goods for international GMP cannabis products and developin
Slide 10: Where GMP Matters
Where GMP Matters Poland The United Germany Kingdom Ukraine Portugal Thailand Brazil Australia New Zealand Global medical cannabis sales are expected to grow to USD $43.72B by 20301. Most emerging markets have mandated good manufacturing practice requirements to import, manufacture, package and sell
Slide 11: Commercializing GMP Capabilities
Commercializing GMP Capabilities HYTN Receives Order for GMP Cannabis Goods Processing Only GMP Wholesaling HYTN Receives Cannabis from LP that HYTN Procures Cannabis Flowers to Meet Requires Processing International Distributor Demand HYTN Processes Cannabis (Final Dry, Final Trim, Testing, Weight,
Slide 12: Growth in Medical Cannabis and Clinical Psychedelics
Growth in Medical Cannabis and Clinical Psychedelics The global medical cannabis market and clinical psychedelics industry are undergoing substantial growth. HYTN possesses the licenses, expertise and track record to address both immediate and future global demands. Cannabinoids and Psychedelics are
Slide 13: Proprietary Elevation Technology
Proprietary ® Elevation Technology HYTN has developed a proprietary active ingredient delivery technology allowing for an enhanced product experience. Elevation Technology® ensures consistent quality and improves the user experience of our products Industry-Leading Elevation Technology® combines nan
Slide 14: Elevated Products
Elevated Products Emulsions infused with Elevation Technology® HYTN’s infused emulsions combine all-natural ingredients with our Elevation Technology® delivering heightened experiences • 0 Calories • 0 Carbs • Sugar-Free • Gluten-Free • Natural Ingredients HYTN's Edibles are a combination of all-nat
Slide 15: Our Team
Our Team HYTN’s team is comprised of industry professionals with diverse backgrounds in CPG Manufacturing, Molecular Genetics, Cannabis Cultivation and Drug Manufacturing Elliot McKerr - CEO Jason Broome - COO Dr. Philippe Henry - Strategic Advisor Rick Brar – Strategic Advisor As the founder and pr
Slide 16: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Information These materials include forward-looking statements. Such statements are based on our current beliefs a nd expectations a nd are inherently subject to significant business, economic a nd competitive uncertainties a nd contingencies, man
Slide 17: HYTN Innovations
HYTN INNOVATIONS www.hytn.ca info@hytn.ca 1.866.590.9289